Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
FAIL · Does not pass the screen
10.35 USD
Price as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 16:51 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price10.35 USD at the 3 Nov 2026 close
Our value readFair vs our fair value, as of 3 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.14, read 2026-11-02
Ethical does not pass the values gate
Price10.35 USD
Fair value10.07
Ethical score70.0/100
Value readFairas of 3 Nov 2026
Our investment reviews on this name
2026-10-02Read Markup8.20+26.2% to today ✓Markdown gives way to Markup after a 5% rise in 2 weeks
2026-09-17Read Markdown7.78+33.0% to today Markup gives way to Markdown after a 7% slide in 4 weeks
2026-08-18Read Markup8.33+24.2% to today ✓Accumulation gives way to Markup after a 23% rise in 7 weeks
2026-07-02Read Accumulation6.79+52.4% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Xeris Biopharma Holdings, Inc. holds its Markup at $10.35. The statistical read favours the sellers, held for 51 days.
As held on the ledger · 2026-11-03
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 51 days
Price at the screen
$10.35
Valuation
N/A trailing · 29.35 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.84
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
67.30%
Below 33%
Interest-bearing debt is 67.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
42.26%
Below 49%
Money owed to the company is 42.3% of assets, under the 49% limit.
Pass
Revenue purity
1.62%
Below 5%
Only 1.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Xeris Biopharma Holdings,'s business is in a permissible area, but its interest-bearing debt is about 67% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when XERS's ethical verdict changes
Today XERS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades above our $10.07 fair value estimate, 28.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. The price runs 2.8% above the base estimate.
Third-party analyst targets. The average target sits +16% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
XERS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$10.35-3.4%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$10.71+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$10.71+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$10.71+5.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$10.20+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$10.20+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$10.20-6.1%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$10.86+11.2%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 38% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
2026-10-21Markup$9.77-6.8%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter.
2026-10-14Markup$10.48+27.8%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 27.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 47%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (7 analysts) rates it none, with a mean price target of $11. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
